HER2 Amplification: Mechanism, Targeted Therapy, and Resistance

HER2 Biology and Amplification Mechanism

HER2 is unique among the four ErbB family receptors in lacking a known high-affinity direct ligand, instead serving as the preferred heterodimerisation partner for EGFR, HER3, and HER4. The HER2 kinase domain is constitutively active and functions as the 'activator' kinase in asymmetric dimers, phosphorylating the partner ('receiver') receptor and creating docking sites for downstream signalling proteins. In HER2-amplified tumours, the massive increase in receptor density drives spontaneous receptor clustering and constitutive homodimerisation at densities sufficient for ligand-independent signalling.

HER2 amplification involves the 17q12 region and can co-amplify neighbouring genes such as GRB7. Laboratories may assess protein expression by immunohistochemistry and gene copy status by in-situ hybridisation or sequencing. Scoring rules and reflex-testing requirements are disease- and guideline-specific; a threshold copied from breast cancer should not automatically be applied to gastric, colorectal or other tumours.

Antibody-Drug Conjugates: T-DM1 and T-DXd

Trastuzumab emtansine (T-DM1) links a HER2-binding antibody to the microtubule-directed payload DM1 with a non-cleavable linker. After receptor binding and internalisation, lysosomal processing releases payload-containing catabolites. Its labelled uses are disease- and treatment-history-specific and should be checked in current prescribing information.

Trastuzumab deruxtecan (T-DXd) uses a cleavable linker and a topoisomerase-I-inhibitor payload. Its membrane-permeable payload can contribute to a bystander effect within heterogeneous tumour tissue. Trials have studied expression categories beyond traditional HER2-positive breast cancer, but terminology, scoring and labelled populations continue to be assay- and disease-specific.

Resistance to HER2-Targeted Therapy

Primary or acquired resistance can involve incomplete HER2 dependency, PIK3CA-pathway activation, PTEN loss, truncated HER2 forms, altered trafficking, drug-efflux or compensatory receptor signalling. Frequencies and causal strength vary across studies, and a co-alteration does not guarantee resistance in an individual tumour.

Antibodies, antibody–drug conjugates and HER-family kinase inhibitors engage different parts of the system and have been studied in different disease and treatment-history settings. Landmark trials can explain the evidence path, but current selection, brain-metastasis language, sequencing and safety requirements should be taken from the latest label and guideline.

HER2 Across Tumour Types: Gastric, Lung, and Colorectal

HER2 amplification or overexpression occurs in subsets of gastric and gastro-oesophageal cancers, where scoring differs from breast cancer because staining can be heterogeneous. Trials such as ToGA and later antibody–drug-conjugate studies established disease-specific evidence. They do not establish that any level of HER2 expression is actionable regardless of tissue origin.

In NSCLC, activating ERBB2 sequence variants—often exon 20 insertions—are mechanistically distinct from amplification and protein overexpression. Colorectal and other cancers use their own biomarker definitions and combination evidence. A report should therefore state whether the finding is mutation, amplification or expression and match it to a current disease-specific source.

Key Takeaways

• ·HER2 amplification can increase receptor density and HER-family dimer signalling, but amplification, expression and activating mutations are distinct biomarkers.
• ·HER2-directed antibodies, conjugates and kinase inhibitors have different mechanisms, labelled populations and safety profiles.
• ·A bystander-capable payload can affect nearby cells in heterogeneous tissue, but HER2 expression categories and eligibility remain assay- and disease-specific.
• ·PI3K-pathway changes, receptor adaptation and drug-handling mechanisms can contribute to resistance without acting as universal predictors.
• ·HER2 evidence now spans several cancers, yet tissue lineage and alteration class remain central rather than replaced by one pan-tumour rule.